Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

E. R. Squibb

John Ripley Myers

William McLaren Bristol

Bristol-Myers Squibb Company

Acerta Pharma, an affiliate of AstraZeneca, develops and delivers targeted novel transformational medicines for patients with hematological malignancies.  Acerta Pharma uses innovative approaches to discover, develop, and deliver targeted medicines, focusing on innovative clinical strategies and resistance biology.

Acerta Pharma

AI in Pharma: Discovery is focused on exploring the applications of AI-based technology in drug discovery and development, specifically how AI, ML, NLP, data science, and generative deep learning models can optimize the pharmaceutical and biotechnology industries.

AI in Pharma: Discovery

Cordia Pharma LTD UK operates in the healthcare industry, providing business process optimization, technology solutions, strategic sourcing, and digital transformation services. This description is self-described.

Metric
Company Name	Bristol-Myers Squibb Company	Acerta Pharma	AI in Pharma: Discovery	Cordia Pharma LTD UK
Symbol	BMY
MSH ID	COM:BMS	COM:ACERTA-PHARMA	COM:AIINPHARMA-DISCOVERY	COM:CORDIAPHARMA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Commercial & Professional Services
Industry	Drug Manufacturers - General	Pharmaceutical	Pharmaceuticals	Healthcare & Health Services
Country	US	NL	US	GB
Stage
Employee Count	34.10K
Website	bms.com	acerta-pharma.com	aiinpharma-discovery.com	cordiapharma.com
LinkedIn				cordia-pharma-ltd
Founders

Metric
Market Cap	83.35B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	45.01B
Revenue (LTM)
Revenue (NTM)
Gross Profit	34.31B
EBITDA	19.18B
Operating Income	17.24B
Net Income	8.03B
EPS	3.88
Diluted EPS	3.86
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.76
Operating Profit Margin	0.31
EBITDA Margin	0.43
Net Profit Margin	0.18
Return on Equity	0.26
Return on Assets	0.08
Return on Capital Employed	0.19

COM:BMS

Bristol Myers Squibb

Last Close

58.23

22/11 21:00

Market Cap

83.35B

Beta: -

Volume Today

7.37M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	11.94
P/B Ratio	3.41
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.36
EV Multiple	4.18

Metric
Days Sales Outstanding	127.10
Days Payables Outstanding	97.40
Days Inventory Outstanding	98.52
Operating Cycle	214.66
Cash Conversion Cycle	103.41
Asset Turnover	0.49

Metric
Operating Cash Flow	13.86B
Free Cash Flow	12.65B
Cash Flow to Debt	0.33
Operating Cash Flow/Sales	0.31
Free Cash Flow Yield	0.12

Metric
Cash & Equivalents	11.46B
Accounts Receivable	-995M
Inventory	2.66B
Goodwill	21.17B
Debt to Capitalization	0.78
Debt to Assets	0.43
Current Ratio	1.18
Quick Ratio	1.24

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.21
SG&A to Revenue